+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report by Linker (Cleavable, Non-Cleavable), Condition (Myeloma, Lymphoma, Breast Cancer), and Region with Growth Forecasts, 2025-2030- Product Image
Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report by Linker (Cleavable, Non-Cleavable), Condition (Myeloma, Lymphoma, Breast Cancer), and Region with Growth Forecasts, 2025-2030- Product Image
New

Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report by Linker (Cleavable, Non-Cleavable), Condition (Myeloma, Lymphoma, Breast Cancer), and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 100 Pages
  • February 2025
  • Region: Global
  • Grand View Research
  • ID: 5450247
Description Jump to:
The Antibody Drug Conjugates Contract Manufacturing Market was valued at USD 8.87 billion in 2024, and is projected to reach USD 16.55 billion by 2030, rising at a CAGR of 10.99%. The factors driving the industry growth include the complex nature of antibody drug conjugates (ADCs) contributing to the demand for contract manufacturing, the increasing number of research on antibody therapies, and the rise in cancer incidence. During the pandemic, the clinical trials for cancer were stopped for a short period. However, owing to the severity of the disease, the trials were started again. As per the IQVIA Oncology Trends Report 2022, the number of clinical trials for cancer is growing.

The IQVIA report states that there was a 56% increase in oncology clinical trials between 2016 and 2021. This number of clinical studies is expected to rise even further owing to the growing prevalence of cancer worldwide. This is expected to support the ADC development and manufacturing activities, thus supporting industry growth post-pandemic. Antibody drug conjugates have high efficiency in treating cancer as it only targets the cancerous cells and does not affect the healthy cells of the body. As a result, several biopharmaceutical companies have received significant funding for ADC-related research.

For instance, in October 2022, Mablink Bioscience, raise USD 31 million from Series A funding to build its antibody drug conjugate pipeline. Thus, heavy investments in the R&D of ADCs are expected to improve their availability in the coming years and thus support the demand for ADC contract manufacturing. In September 2021, the U.S. FDA provided accelerated approval for ADC tisotumab vedotin-tftv for treating adult patients with recurrent or metastatic cervical cancer with disease progression or after chemotherapy. Such approvals, in the coming years, are expected to boost the demand for contract manufacturing services for ADC.

Antibody Drug Conjugates Contract Manufacturing Market Report Highlights

  • Based on condition, the market includes myeloma, lymphoma, breast cancer and others. The myeloma segment led the market with the largest revenue share of 49.61% in 2024. The lymphoma segment is anticipated to witness the fastest CAGR during the forecast period.
  • Based on linker, the market is segmented into cleavable linkers and non-cleavable linkers. The cleavable linkers segment led the market with the largest revenue share of 56.1% in 2024.
  • The antibody drug conjugates contract manufacturing market in North America is expected to witness the fastest CAGR over the forecast period.
  • Asia Pacific antibody drug conjugates contract manufacturing market dominated the market with the largest revenue share of 40.93% in 2024. The regional growth is primarily owing to supportive regulatory reforms, especially in countries such as India & China, and low-cost labor.

This report addresses:

  • Market intelligence to enable effective decision-making.
  • Market estimates and forecasts from 2018 to 2030.
  • Growth opportunities and trend analyses.
  • Segment and regional revenue forecasts for market assessment.
  • Competition strategy and market share analysis.
  • Product innovation listings for you to stay ahead of the curve.
  • COVID-19's impact and how to sustain in this fast-evolving market.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Regional Scope
1.1.2. Estimates And Forecast Timeline
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Parent Market Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
1.10.1. Objective-1
1.10.2. Objective-2
1.10.3. Objective-3
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising Incidence of Cancer
3.2.1.2. High Cost of Manufacturing ADC and Challenges Associated With Manufacturing Contributing to the Demand for Contract Manufacturing
3.2.1.3. Increasing R&D Activities on ADCs
3.2.2. Market Restraint Analysis
3.2.2.1. Quality Issues While Outsourcing
3.2.2.2. Limited Outsourcing Opted by Big Biopharma Companies
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Industry Ecosystem Analysis
3.6. Market Analysis Tools
3.6.1. Porter’s Five Forces Analysis
3.6.2. PESTEL Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Antibody Drug Conjugates (ADC) Contract Manufacturing Market: Condition Estimates & Trend Analysis
4.1. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition: Segment Dashboard
4.2. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition: Movement Analysis
4.3. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates & Forecasts, by Condition, 2018-2030 (USD Million)
4.4. Myeloma
4.4.1. Myeloma Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.5. Lymphoma
4.5.1. Lymphoma Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.6. Breast Cancer
4.6.1. Breast Cancer Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.7. Others
4.7.1. Others Market Estimates and Forecasts, 2018 to 2030 (USD Million)
Chapter 5. Antibody Drug Conjugates (ADC) Contract Manufacturing Market: Linker Estimates & Trend Analysis
5.1. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker: Segment Dashboard
5.2. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker: Movement Analysis
5.3. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates & Forecasts, by Linker, 2018-2030 (USD Million)
5.4. Cleavable Linker
5.4.1. Cleavable Linker Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.5. Non-Cleavable Linker
5.5.1. Non-Cleavable Linker Market Estimates and Forecasts, 2018 to 2030 (USD Million)
Chapter 6. Antibody Drug Conjugates (ADC) Contract Manufacturing Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. North America
6.4.1. North America Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework
6.4.2.4. U.S. Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Competitive Scenario
6.4.3.3. Regulatory Framework
6.4.3.4. Canada Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Competitive Scenario
6.4.4.3. Regulatory Framework
6.4.4.4. Mexico Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5. Europe
6.5.1. Europe Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework
6.5.2.4. UK Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework
6.5.3.4. Germany Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework
6.5.4.4. France Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Competitive Scenario
6.5.5.3. Regulatory Framework
6.5.5.4. Italy Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Competitive Scenario
6.5.6.3. Regulatory Framework
6.5.6.4. Spain Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.7. Sweden
6.5.7.1. Key Country Dynamics
6.5.7.2. Competitive Scenario
6.5.7.3. Regulatory Framework
6.5.7.4. Sweden Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.8. Denmark
6.5.8.1. Key Country Dynamics
6.5.8.2. Competitive Scenario
6.5.8.3. Regulatory Framework
6.5.8.4. Denmark Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.9. Norway
6.5.9.1. Key Country Dynamics
6.5.9.2. Competitive Scenario
6.5.9.3. Regulatory Framework
6.5.9.4. Norway Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework
6.6.2.4. Japan Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework
6.6.3.4. China Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Competitive Scenario
6.6.4.3. Regulatory Framework
6.6.4.4. India Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.5. Thailand
6.6.5.1. Key Country Dynamics
6.6.5.2. Competitive Scenario
6.6.5.3. Regulatory Framework
6.6.5.4. Thailand Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.6. South Korea
6.6.6.1. Key Country Dynamics
6.6.6.2. Competitive Scenario
6.6.6.3. Regulatory Framework
6.6.6.4. South Korea Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.7. Australia
6.6.7.1. Key Country Dynamics
6.6.7.2. Competitive Scenario
6.6.7.3. Regulatory Framework
6.6.7.4. Australia Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Competitive Scenario
6.7.2.3. Regulatory Framework
6.7.2.4. Brazil Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Competitive Scenario
6.7.3.3. Regulatory Framework
6.7.3.4. Argentina Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8. MEA
6.8.1. MEA Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Competitive Scenario
6.8.2.3. Regulatory Framework
6.8.2.4. South Africa Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Competitive Scenario
6.8.3.3. Regulatory Framework
6.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Competitive Scenario
6.8.4.3. Regulatory Framework
6.8.4.4. UAE Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Competitive Scenario
6.8.5.3. Regulatory Framework
6.8.5.4. Kuwait Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Market Participant Categorization
7.1.1. Market Leaders
7.1.2. Emerging Players
7.2. Company Market Share/Assessment Analysis, 2024
7.3. Company Profiles
7.3.1. Sterling
7.3.1.1. Company Overview
7.3.1.2. Financial Performance
7.3.1.3. Service Benchmarking
7.3.1.4. Strategic Initiatives
7.3.2. Recipharm AB
7.3.2.1. Company Overview
7.3.2.2. Financial Performance
7.3.2.3. Service Benchmarking
7.3.2.4. Strategic Initiatives
7.3.3. Lonza
7.3.3.1. Company Overview
7.3.3.2. Financial Performance
7.3.3.3. Service Benchmarking
7.3.3.4. Strategic Initiatives
7.3.4. Catalent, Inc.
7.3.4.1. Company Overview
7.3.4.2. Financial Performance
7.3.4.3. Service Benchmarking
7.3.4.4. Strategic Initiatives
7.3.5. Sartorius AG
7.3.5.1. Company Overview
7.3.5.2. Financial Performance
7.3.5.3. Service Benchmarking
7.3.5.4. Strategic Initiatives
7.3.6. Wuxi Biologics
7.3.6.1. Company Overview
7.3.6.2. Financial Performance
7.3.6.3. Service Benchmarking
7.3.6.4. Strategic Initiatives
7.3.7. Samsung Biologics
7.3.7.1. Company Overview
7.3.7.2. Financial Performance
7.3.7.3. Service Benchmarking
7.3.7.4. Strategic Initiatives
7.3.8. Piramal Group (Piramal Pharma Solutions)
7.3.8.1. Company Overview
7.3.8.2. Financial Performance
7.3.8.3. Service Benchmarking
7.3.8.4. Strategic Initiatives
7.3.9. AbbVie, Inc. (AbbVie Contract Manufacturing)
7.3.9.1. Company Overview
7.3.9.2. Financial Performance
7.3.9.3. Service Benchmarking
7.3.9.4. Strategic Initiatives
7.3.10. Merck KGaA
7.3.10.1. Company Overview
7.3.10.2. Financial Performance
7.3.10.3. Service Benchmarking
7.3.10.4. Strategic Initiatives
List of Tables
Table 1 Information Procurement
Table 2 Primary Research Pattern
Table 3 Market Research Approaches
Table 4 Value Chain-Based Sizing & Forecasting
Table 5 Market Formulation & Validation
Table 6 Antibody Drug Conjugates (ADC) Contract Manufacturing, Market Segmentation
Table 7 Market Driver Relevance Analysis (Current & Future Impact)
Table 8 Market Restraint Relevance Analysis (Current & Future Impact)
Table 9 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
Table 10 Porter’s Five Forces Analysis
Table 11 Regional Marketplace: Key Takeaways
Table 12 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Myeloma, 2018-2030 (USD Million)
Table 13 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Lymphoma, 2018-2030 (USD Million)
Table 14 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Breast Cancer, 2018-2030 (USD Million)
Table 15 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Others, 2018-2030 (USD Million)
Table 16 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Cleavable Linker, 2018-2030 (USD Million)
Table 17 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Non-cleavable Linker, 2018-2030 (USD Million)
Table 18 Regional Outlook, 2024 & 2030
Table 19 North America Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 20 U.S. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 21 Canada Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 22 Mexico Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 23 Europe Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 24 UK Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 25 Germany Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 26 France Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 27 Italy Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 28 Spain Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 29 Denmark Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 30 Sweden Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 31 Norway Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 32 Asia Pacific Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 33 India Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 34 China Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 35 Japan Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 36 South Korea Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 37 Australia Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 38 Thailand Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 39 Latin America Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 40 Brazil Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 41 Argentina Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 42 MEA Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 43 South Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 44 Saudi Arabia Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 45 UAE Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
Table 46 Kuwait Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018-2030 (USD Million)
List of Figures
Figure 1 List of Secondary Sources
Figure 2 List of Abbreviations
Figure 3 Global Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 4 Global Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 5 Global Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Region, 2018-2030 (USD Million)
Figure 6 North America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Country, 2018-2030 (USD Million)
Figure 7 North America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 8 North America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 9 U.S. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 10 U.S. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 11 Canada Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 12 Canada Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 13 Mexico Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 14 Mexico Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 15 Europe Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Country, 2018-2030 (USD Million)
Figure 16 Europe Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 17 Europe Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 18 Germany Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 19 Germany Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 20 UK Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 21 UK Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 22 France Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 23 France Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 24 Italy Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 25 Italy Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 26 Spain Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 27 Spain Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 28 Denmark Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 29 Denmark Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 30 Sweden Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 31 Sweden Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 32 Norway Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 33 Norway Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 34 Asia Pacific Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Country, 2018-2030 (USD Million)
Figure 35 Asia Pacific Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 36 Asia Pacific Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 37 China Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 38 China Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 39 Japan Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 40 Japan Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 41 India Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 42 India Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 43 South Korea Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 44 South Korea Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 45 Australia Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 46 Australia Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 47 Thailand Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 48 Thailand Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 49 Latin America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Country, 2018-2030 (USD Million)
Figure 50 Latin America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 51 Latin America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 52 Brazil Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 53 Brazil Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 54 Argentina Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 55 Argentina Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 56 Middle East & Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Country, 2018-2030 (USD Million)
Figure 57 Middle East & Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 58 Middle East & Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 59 South Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 60 South Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 61 Saudi Arabia Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 62 Saudi Arabia Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 63 UAE Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 64 UAE Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)
Figure 65 Kuwait Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018-2030 (USD Million)
Figure 66 Kuwait Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018-2030 (USD Million)

Companies Mentioned

The major companies profiled in this Antibody Drug Conjugates Contract Manufacturing market report include:
  • Sterling
  • Recipharm AB
  • Lonza
  • Catalent, Inc.
  • Sartorius AG
  • Wuxi Biologics
  • Samsung Biologics
  • Piramal Group (Piramal Pharma Solutions)
  • AbbVie, Inc. (AbbVie Contract Manufacturing)
  • Merck KGaA

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedFebruary 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 8.87 Billion
Forecasted Market Value ( USD ) by 2030 $ 16.55 Billion
Compound Annual Growth Rate10.9%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable, Non-cleavable), By Product, By Target, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable, Non-cleavable), By Product, By Target, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 125 Pages
  • Global
From
Antibody Drug Conjugates Contract Manufacturing Market by Linker, Condition, End Use - Global Forecast 2025-2030 - Product Image

Antibody Drug Conjugates Contract Manufacturing Market by Linker, Condition, End Use - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Antibody Drug Conjugates Contract Manufacturing Market Report 2024 - Product Image

Antibody Drug Conjugates Contract Manufacturing Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Antibody Drug Conjugate Market by Mechanism of Action, Drugs, Technology, Indication, End User - Global Forecast 2025-2030 - Product Image

Antibody Drug Conjugate Market by Mechanism of Action, Drugs, Technology, Indication, End User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions - Product Image

Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions

  • Report
  • 716 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.